Nucleotide analogue bemnifosbuvir inhibits hepatitis E virus replication in preclinical models - PubMed
3 days ago
- #Antiviral therapy
- #Hepatitis E virus
- #Bemnifosbuvir
- Bemnifosbuvir (BEM), a nucleotide analogue, effectively inhibits Hepatitis E virus (HEV) replication in preclinical models.
- The study developed an image-based screening platform using a full-length HEV fluorescence reporter virus to identify potent HEV inhibitors.
- BEM showed dose-dependent suppression of HEV replication in vitro and in vivo with minimal cytotoxicity.
- Combining BEM with ribavirin resulted in an additive antiviral effect against HEV.
- HEV-3 remains susceptible to BEM over extended treatment, reducing concerns about rapid viral resistance development.
- BEM significantly reduced HEV viral loads and liver inflammation in a gerbil infection model.
- Given BEM's favorable safety profile, it is suggested for investigation in patients with chronic HEV infection.